Month: January 2023

OLNEY, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) — Sandy Spring Bancorp, Inc. (Nasdaq: SASR) will announce its fourth quarter earnings on Thursday, January 26, 2023. The company will hold a conference call that day at 2:00 p.m. (ET) to discuss results and answer questions. The conference call will be webcast live through the Sandy Spring Bank website. Those who wish to participate in order to ask questions may do so by calling 1- 844-200-6205; please use Access Code: 970945. Those who wish to listen to the call should go to the Investor Relations page of www.sandyspringbank.com and log on 10 minutes ahead of the scheduled start of the call. An internet-based replay will be available on the Investor Relations page of the website until February 9, 2023. A telephone voice replay will also be available during that same time period at 1-866-813-9403....

DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PT in San Francisco, CA. An audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days. About Chimerix Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage...

IRVINE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global provider of secure turnkey solutions for the Industrial Internet of Things (IoT) and the Intelligent IT market, today announced that its CFO, Jeremy Whitaker, will present at the 25th Annual Needham Virtual Growth Conference on Jan. 11, 2023 at 2:15 p.m. Eastern Standard Time. A webcast of the presentation will be available live via the link below. In addition, a replay of the presentation will remain available at the webcast link for 30 days after the presentation. Webcast Link: https://wsw.com/webcast/needham128/ltrx/2301602 Lantronix management will also hold in-person, one-on-one meetings on Jan. 10 and 11. To book a one-on-one meeting, please contact your Needham salesperson.        About Lantronix Lantronix Inc. is a global provider...

VANCOUVER, British Columbia, Jan. 05, 2023 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to announce the appointments of Rob Henderson as Vice President, Technical Services and Kevin MacKenzie as Vice President, Corporate Development & Investor Relations. Patrick Downey, President and CEO stated, “I am extremely pleased that Rob and Kevin have joined our team. Both are well-regarded industry professionals with significant worldwide experience in management, operations, exploration, capital markets and M&A. Rob is a proven mining executive with extensive global operations and development experience including West Africa as VP Technical Services for Kinross Gold. Rob will lead Orezone’s technical teams, ensuring ongoing operational excellence, and provide technical...

WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer. Dr. Baumal replaces Federico Grossi, M.D., Ph.D., who plans to remain at Apellis until February 28, 2023 to help with the transition and preparations for the potential launch of pegcetacoplan for geographic atrophy (GA). “Caroline is a world-renowned retina specialist who has been at the forefront of retina research and patient care for over 25 years, and we are thrilled to welcome her to Apellis,” said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder of Apellis. “Caroline’s expertise and deep understanding of GA will be a tremendous asset as...

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2023. “2022 marked a successful year of continued clinical and corporate accomplishments for ALX Oncology. Marked by steady progress in the clinical development of our lead program, evorpacept, for the treatment of multiple solid tumor indications and hematological malignancies, we expanded clinical development of evorpacept in new indications and combinations. These included a Phase 1 trial in urothelial cancer (“UC”) in combination with PADCEV®, an investigator-sponsored Phase 2 trial in refractory microsatellite stable metastatic...

Figure 1 White Gold Property OverviewFigure 2 2022 Ryan’s Surprise DrillingFigure 3 WHTRS22D029 Cross SectionFigure 4 WHTRS22D029 Core 266.50m to 278mFigure 5 Ryan’s Surprise Gold Zones Isometric ModelTORONTO, Jan. 05, 2023 (GLOBE NEWSWIRE) — White Gold Corp. (TSX.V: WGO, OTCQX: WHGOF, FRA: 29W) (the “Company”) is pleased to report positive assay results for its 2022 diamond drilling program on the Ryan’s Surprise target, which is located approximately 2km west of its flagship Golden Saddle and Arc deposits and 11km south of the Company’s VG deposit on the Ryan’s Trend, a 6.5km long x 1km wide north-northwest trend of anomalous gold and arsenic in soils (Figure 1). Hole WHTRS22D029 encountered several zones of significant gold mineralization including 5.34 g/t Au over 10.85m and represents a 50m extension...

– Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 – – Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for wet AMD and Phase 2 PAVIA clinical trial for NPDR – – Full-year 2022 net product revenue estimated to exceed $39.5 million versus $35.3 million in 2021 – – Cash and investments of approximately $144 million as of December 31, 2022 – WATERTOWN, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced a business update and key 2023 clinical timelines for its lead product candidate, EYP-1901. EYP-1901 is an investigational sustained delivery product for serious retinal diseases that uses a bioerodible...

Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects Fosgonimeton Phase 2/3 LIFT-AD study in mild-to-moderate Alzheimer’s disease is progressing with targeted enrollment completion in mid-2023 and topline data in early 2024 ATH-1105 candidate for amyotrophic lateral sclerosis (ALS) is targeted for IND filing in 2023 BOTHELL, Wash., Jan. 05, 2023 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today provided an update on its pipeline development programs and outlook for 2023. “Our dedication to advancing new therapeutics to impact neurodegenerative diseases remains...

All three patients exceeded the median progression-free survival (PFS) of seven months with two ongoing responses extending beyond 1.5 years and 1.2 years progression-free, respectively, in initial data from Cohort 2 of the Phase 1 INB-200 trial in newly diagnosed glioblastoma multiforme (GBM).Company-sponsored Phase 2 multi-center clinical trial of autologous INB-400 gamma-delta T cells in newly diagnosed GBM patients to start enrollment by Q3 2023.Submission of Investigational New Drug Application (IND) for the Phase 1b trial of INB-410, a genetically modified allogeneic gamma-delta T cell therapy in relapsed and newly diagnosed GBM anticipated in 2H 2023.Announcement of a new solid tumor indication with relevant data at a scientific conference in 1H 2023.NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq:...